Latest News and Press Releases

Sunstone Therapies Announces Start of First Study of Multiple Doses of Psilocybin in Treatment of Depression in Patients with Cancer Phase 2 study to examine safety and efficacy of up to two...

Sunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting Rockville, Maryland, May...

Phase 2 data shows sustained response in 80% of patients and 50% of patients in full remission of depressive symptoms Use of group setting and 1:1 patient to therapist ratio has...

KNOXVILLE, Tenn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Ketamine Media announced today that it is in the final stages of launching its digital ecosystem of premium online properties to raise awareness...

Multi-centre, double-blind randomised controlled phase II trial will investigate the efficacy of COMP360 psilocybin therapy in anorexia nervosa for which there is currently no approved pharmacological...

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022        COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022        COMPASS...

Pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust London, UK, 24 March 2022  COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”),...

London, UK and New York, US, 19 January 2022  COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...